Table 1.
Participant characteristics
| Characteristic | Overall, N = 63 | IV Ig, N = 21 | Oral antibiotics, N = 42 |
|---|---|---|---|
| Age at registration (y) | |||
| Mean (SD) | 70 (8) | 72 (9) | 70 (8) |
| Median | 69 | 69 | 70 |
| Range | 48-87 | 57-87 | 48-87 |
| Sex, n (%) | |||
| Female | 34 (54.0) | 13 (61.9) | 21 (50.0) |
| Male | 29 (46.0) | 8 (38.1) | 21 (50.0) |
| ECOG performance status, n (%) | |||
| 0 | 27 (42.9) | 8 (38.1) | 19 (45.2) |
| 1 | 26 (41.3) | 11 (52.4) | 15 (35.7) |
| 2 | 9 (14.3) | 2 (9.5) | 7 (16.7) |
| Not performed | 1 (1.6) | 0 (0.0) | 1 (2.4) |
| Diagnosis at screening, n (%) | |||
| CLL | 29 (46.0) | 8 (38.1) | 21 (50.0) |
| MM | 12 (19.0) | 3 (14.3) | 9 (21.4) |
| NHL | 20 (31.7) | 8 (38.1) | 12 (28.6) |
| Other | 2 (3.2) | 2 (9.5) | 0 (0.0) |
| Disease therapy n (%) | |||
| Currently receiving systemic anticancer treatment | 15 (24.2) | 6 (28.6) | 9 (22.0) |
| In remission having previously received systemic anticancer treatment | 21 (33.9) | 8 (38.1) | 13 (31.7) |
| Never received systemic anticancer treatment | 17 (27.4) | 4 (19.0) | 13 (31.7) |
| Relapsed or refractory disease, having previously received systemic anticancer treatment | 8 (12.9) | 3 (14.3) | 5 (12.2) |
| Other | 1 (1.6) | 0 (0.0) | 1 (2.4) |
| Missing | 1 (1.6) | 0 | 1 (2.4) |
| IgG level at enrollment (g/L), median (IQR) | 4.1 (3.1-5.2) | 4.5 (3.1-5.8) | 4.0 (3.2-4.5) |
| IgG level < 4 g/L, n (%)∗ | 28 (45.2) | 8 (38.1) | 20 (48.8) |
| History of infection, n (%) | 59 (93.7) | 20 (95.2) | 39 (92.9) |
| Prior pneumococcal vaccination, n (%) | 29 (46) | 9 (43) | 20 (48) |
ECOG, European Cooperative Oncology Group; SD, standard deviation.
∗
Missing data for 1 participant in the oral antibiotic arm.